Home › Companies › ARBUTUS BIOPHARMA CORP. › 2024-2025
Compiled from SEC Form N-PX filings and ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 23, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of May 21, 2025: 7 items on ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 23, 2025: 2 approved · 5 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore ARBUTUS BIOPHARMA CORP. in the interactive database Compare manager voting policies
These tallies are ARBUTUS BIOPHARMA CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Lindsay Androski, JD, MBA, CFA | 123,784,223 | -- | -- | 6,331,634 | 28,231,130 | 95% | Not verified | — |
| Elect Director: Robert Alan Beardsley | 124,837,983 | -- | -- | 5,277,874 | 28,231,130 | 96% | Not verified | — |
| Elect Director: Joseph Bishop | 122,059,590 | -- | -- | 8,056,267 | 28,231,130 | 94% | Not verified | — |
| Elect Director: Matthew Gline | 122,656,045 | -- | -- | 7,459,812 | 28,231,130 | 94% | Not verified | — |
| Elect Director: Anuj Hasija | 124,821,361 | -- | -- | 5,294,496 | 28,231,130 | 96% | Not verified | — |
| 2. Approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Company's Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities and Exchange Commission on April 4, 2025 | 122,791,749 | 6,976,561 | 347,547 | -- | 28,231,130 | 95% | Approved | — |
| 3. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 157,702,833 | 486,002 | 158,152 | -- | -- | 99.6% | Approved | — |
Source: ARBUTUS BIOPHARMA CORP., Form 8-K, filed with the SEC on May 23, 2025 — read the filing on EDGAR.
Each item below shows how the 137 asset managers that disclosed a ARBUTUS BIOPHARMA CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Anuj Hasija
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Anuj Hasija”): 124,821,361 for, 5,294,496 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 27,883,253 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Joseph Bishop
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Joseph Bishop”): 122,059,590 for, 8,056,267 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 26,569,049 for, 1,314,204 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,222,747 | 0 | 0 | 14,095 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,196,192 | Withhold |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 87,217 | Withhold |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Lindsay Androski, JD, MBA, CFA
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Lindsay Androski, JD, MBA, CFA”): 123,784,223 for, 6,331,634 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 27,841,928 for, 41,325 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 40,720 | Withhold |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Matthew Gline
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Matthew Gline”): 122,656,045 for, 7,459,812 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 26,569,049 for, 1,314,204 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,222,747 | 0 | 0 | 14,095 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,196,192 | Withhold |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 87,217 | Withhold |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Robert Alan Beardsley
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Robert Alan Beardsley”): 124,837,983 for, 5,277,874 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 27,883,253 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.
Combines 7 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“2. Approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Company's Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities ”): 122,791,749 for, 6,976,561 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(2) approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Company's Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities and Exchange Commission on April 4, 2025 (the "Proxy Statement/Circular")”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 342,379 | 0 | 0 | Against |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund | 188,510 | 20,341 | 0 | 1,017 | Mixed |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund II | 105,907 | 11,427 | 0 | 572 | Mixed |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 0 | 34,997 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
Fund voting reports, all 38 managers: 27,786,808 for, 422,630 against, 1,589 withheld. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Morgan Stanley | 22,119,980 | 0 | 0 | 0 | For |
| Whitefort Capital Management, LP | 13,307,967 | 0 | 0 | 0 | For |
| Two Seas Capital LP | 9,272,555 | 0 | 0 | 0 | For |
| BlackRock | 3,295,587 | 54,827 | 0 | 0 | For |
| Woodline Partners LP | 2,552,942 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,195,711 | 0 | 0 | 0 | For |
| State Street | 2,155,368 | 1,481 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,575,941 | 0 | 0 | 0 | For |
| Rangeley Capital, LLC | 1,349,000 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,432 | 0 | 0 | 0 | For |
| Saba Capital Management, L.P. | 925,416 | 31,768 | 1,589 | 0 | For |
| Rubric Capital Management LP | 827,328 | 0 | 0 | 0 | For |
| Northern Trust | 724,242 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 484,461 | 0 | 0 | 0 | For |
| Vanguard | 480,513 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 454,920 | 0 | 0 | 0 | For |
| Wellington | 370,538 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 342,379 | 0 | 0 | Against |
| Nuveen | 313,307 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 294,758 | 0 | 0 | 0 | For |
| UBS | 0 | 267,277 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 214,029 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 147,860 | 33,734 | 0 | 0 | Mixed |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 122,042 | 0 | 0 | 0 | For |
| AllianceBernstein | 120,240 | 0 | 0 | 0 | For |
Institutional-manager reports, all 113 managers: 65,673,637 for, 962,139 against, 1,824 abstained. Showing the 25 largest; see all in the interactive database.
99.6% Approved · of votes cast
Description as filed by funds: To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“3. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 157,702,833 for, 486,002 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 28,209,799 for, 1,081 against, 148 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund | 209,082 | 692 | 0 | 95 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund II | 117,464 | 389 | 0 | 53 | For |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 191,527,129 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.51% |
| 2 | Morgan Stanley | 3.62% |
| 3 | BlackRock | 2.71% |
| 4 | Fidelity | 1.17% |
| 5 | Equitable | 0.76% |
| 6 | Charles Schwab | 0.62% |
| 7 | State Street | 0.34% |
| 8 | Aberdeen | 0.18% |
| 9 | TIAA | 0.16% |
| 10 | Saba Capital Income & Opportunities Fund | 0.11% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Morgan Stanley | 11.55% |
| 2 | Whitefort Capital Management, LP | 6.95% |
| 3 | Two Seas Capital LP | 4.84% |
| 4 | BlackRock | 1.75% |
| 5 | Woodline Partners LP | 1.33% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.15% |
| 7 | State Street | 1.13% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.82% |
| 9 | Rangeley Capital, LLC | 0.70% |
| 10 | Charles Schwab | 0.62% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Matthew Gline | 20.28% | DEF14A |
| Roivant Sciences Ltd. | 20.28% | 13D |
| Morgan Stanley | 13.53% | 13G |
| Two Seas Capital LP | 9.69% | 13G |
| Whitefort Capital Master Fund, LP | 8.25% | 13D |
| Whitefort Capital Management, LP | 6.95% | DEF14A |
| BlackRock | 6.67% | 13F |
| Vanguard Group | 4.67% | 13F |
| State Street | 2.28% | 13F |
| Michael J. McElhaugh | 1.38% | DEF14A |
Percentages above are of 191,527,129 shares outstanding, as reported by ARBUTUS BIOPHARMA CORP. on its Form 10-Q dated May 12, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARBUTUS BIOPHARMA CORP.’s 10-Q dated May 12, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At ARBUTUS BIOPHARMA CORP.'s shareholder meeting held May 21, 2025, in the 2024-2025 proxy season, 137 asset managers reported how they voted on 7 ballot items in their SEC Form N-PX filings, covering 998 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — ARBUTUS BIOPHARMA CORP.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ARBUTUS BIOPHARMA CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 23, 2025.
ARBUTUS BIOPHARMA CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.